Vesotan
Generic Name
Solifenacin Succinate
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vesotan 8 mg tablet | ৳ 6.02 | ৳ 60.20 |
Description
Overview of the medicine
Vesotan 8 mg Tablet is used to treat symptoms of overactive bladder (OAB), such as urinary urgency, increased urinary frequency, and incontinence (involuntary loss of urine). It helps to reduce the number of times you need to urinate and controls urges.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 5 mg once daily. If needed, the dose may be increased to 10 mg once daily, based on clinical response and tolerability. For an 8 mg tablet, the dosage should be strictly as prescribed by the physician.
Elderly
No dose adjustment is generally required, but caution should be exercised in patients with renal or hepatic impairment.
Renal_impairment
For patients with severe renal impairment (creatinine clearance < 30 mL/min), a dose greater than 5 mg is not recommended. Use with caution in moderate impairment.
How to Take
Vesotan 8 mg Tablet should be taken orally, once daily, with or without food. The tablet should be swallowed whole with some liquid and should not be crushed or chewed.
Mechanism of Action
Solifenacin, the active ingredient in Vesotan, is a selective competitive muscarinic M3 receptor antagonist. It works by blocking the M3 receptors predominantly found in the bladder smooth muscle. This action inhibits bladder contraction, thereby increasing bladder capacity and reducing involuntary contractions of the detrusor muscle.
Pharmacokinetics
Onset
Clinical effects are typically observed within a few days, with maximal effects usually seen within 1-2 weeks of treatment.
Excretion
Eliminated via urine (approximately 69%) and feces (approximately 23%).
Half life
Approximately 45-68 hours, allowing for once-daily dosing.
Absorption
Well absorbed from the gastrointestinal tract, achieving peak plasma concentrations (Cmax) within 3-8 hours after oral administration. Bioavailability is approximately 90%.
Metabolism
Extensively metabolized in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. Several metabolites are formed, but only one, 4R-hydroxy solifenacin, is active.
Side Effects
Contraindications
- Urinary retention
- Severe gastrointestinal conditions (e.g., toxic megacolon)
- Uncontrolled narrow-angle glaucoma
- Myasthenia gravis
- Severe hepatic impairment
- Patients undergoing hemodialysis
- Hypersensitivity to solifenacin or any component of the tablet
Drug Interactions
Other Anticholinergic Agents
Concomitant use with other anticholinergic agents may lead to enhanced therapeutic effects and increased incidence of side effects.
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin)
May decrease solifenacin plasma levels, reducing its efficacy.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole)
Co-administration with strong CYP3A4 inhibitors like ketoconazole can significantly increase solifenacin plasma levels. A dose of 5 mg of solifenacin should not be exceeded when co-administered.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include severe anticholinergic effects such as dry mouth, blurred vision, drowsiness, severe constipation, urinary retention, and tachycardia. Treatment should be symptomatic and supportive, including gastric lavage and administration of activated charcoal.
Pregnancy & Lactation
Pregnancy Category C. Vesotan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended during lactation as it is unknown whether solifenacin is excreted in human milk.
Side Effects
Contraindications
- Urinary retention
- Severe gastrointestinal conditions (e.g., toxic megacolon)
- Uncontrolled narrow-angle glaucoma
- Myasthenia gravis
- Severe hepatic impairment
- Patients undergoing hemodialysis
- Hypersensitivity to solifenacin or any component of the tablet
Drug Interactions
Other Anticholinergic Agents
Concomitant use with other anticholinergic agents may lead to enhanced therapeutic effects and increased incidence of side effects.
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin)
May decrease solifenacin plasma levels, reducing its efficacy.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole)
Co-administration with strong CYP3A4 inhibitors like ketoconazole can significantly increase solifenacin plasma levels. A dose of 5 mg of solifenacin should not be exceeded when co-administered.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include severe anticholinergic effects such as dry mouth, blurred vision, drowsiness, severe constipation, urinary retention, and tachycardia. Treatment should be symptomatic and supportive, including gastric lavage and administration of activated charcoal.
Pregnancy & Lactation
Pregnancy Category C. Vesotan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended during lactation as it is unknown whether solifenacin is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2 to 3 years from the date of manufacture, depending on storage conditions.
Availability
Available in pharmacies and hospitals
Approval Status
DGDA approved in Bangladesh
Patent Status
Generic available
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of solifenacin in treating overactive bladder symptoms. Studies have shown significant improvements in urinary frequency, urgency, and incontinence episodes compared to placebo.
Lab Monitoring
- Routine lab monitoring is generally not required for patients on Solifenacin. However, liver and kidney function should be assessed before initiating treatment, especially in patients with pre-existing impairment.
Doctor Notes
- Assess patient's complete medical history, including comorbidities and co-medications, especially those affecting CYP3A4.
- Educate patients on proper administration and potential side effects.
- Monitor for signs of urinary retention, especially in patients with bladder outflow obstruction.
- Consider alternative treatments if anticholinergic side effects are intolerable or efficacy is insufficient after appropriate titration.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not crush, chew, or break the tablet; swallow it whole.
- Report any severe side effects, especially difficulty urinating or allergic reactions, to your doctor immediately.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Vesotan may cause blurred vision, dizziness, or somnolence. Patients should be cautious when driving or operating machinery until they know how the medication affects them.
Lifestyle Advice
- Limit caffeine and alcohol intake, as they can irritate the bladder and worsen OAB symptoms.
- Practice bladder training exercises (e.g., delaying urination for short periods) as advised by your healthcare provider.
- Maintain a healthy weight and regular physical activity.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Vesotan Brand
Other medicines available under the same brand name
